This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Juno Therapeutics Inc.

Drug Names(s): JCAR-014

Description: JCAR014 is an autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T-cell therapy. JCAR-014 uses the Company's chimeric antigen receptor (CAR) modified T-cells.

JCAR014 utilizes a 1:1 ratio of CD4+ and CD8+ T cells, which may improve efficacy while allowing for lower cell doses.

Deal Structure: Juno and Celgene
In June 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of immunotherapies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno's oncology and cell therapy auto-immune product candidates, including Juno's CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen (BCMA) is excluded as a target in this collaboration.

For Juno-originated programs co-developed under the collaboration: